Cancer genomics: The impact of genomic advances in oncology.

M2 PRESSWIRE-18 February 2003-Research and Markets: Cancer genomics: The impact of genomic advances in oncology(C)1994-2003 M2 COMMUNICATIONS LTD

RDATE:02152003

INTRODUCTION, Cancer Genomics: The impact of genomics advances in oncology provides a detailed insight into the use of genomic technology in the cancer market and its future impact on cancer management. The report focuses extensively on the different genomic applications used in diagnosis and treatment of cancer. The brief illustrates the implications that genomics will have on the future of oncology, both from clinical and industry viewpoints., , SCOPE OF THIS REPORT, Overview of pharmacogenetics and its application to cancer therapy, Implications of genomics for cancer therapy, including the impact on development time and cost, and regulatory, patent and ethical issues, , REPORT HIGHLIGHTS, The explosion of information generated by large-scale genomics has resulted in an exponential increase in the number of potential genes and proteins available for therapeutic and diagnostic research and development. As a result of the increased potential, it has been estimated that the whole pharmaceutical industry, currently valued at $340 billion could grow to $3 trillion by 2020., , KEY REASONS TO BUY THIS REPORT, Identify the key genomic applications in cancer management, Enhance your product''s commercial viability by making detailed comparative analysis of the strategies used by the current players in the market, Maximize the potential of genomics by identifying current and pipeline cancer products incorporating the new technology, Identify potential areas for investment through the brief''s focus on the future impact of genomics in oncology,

For a complete index of this report click on http://www.researchandmarkets.com/reports/1223

Report Index:

HEALTHCARE

Contact details

SECTION 1 ACTION POINTS

OVERVIEW OF CANCER GENOMICS

Cancer genes

Milestones in cancer genetics

Two-horse race for mapping the human genome mapping

Blueprint completed

GENOMIC APPLICATIONS IN CANCER

Diagnosis

Pharmacogenomics and diagnostics

Pharmacogenomics and screening

Pharmacogenetics and treatment

Pharmacogenomics and side-effect minimization

Targeted therapies

Prognosis

Prophylaxis

Prophylactic measures

Chemoprevention

IMPLICATIONS FOR GENOMICS IN CANCER

Increase in the number of new drug targets

But also a spike in failure rates

Financial pressures

Old dogs, new tricks

Alliances with diagnostics companies

Decrease in development time and cost

Positive factors

Negative factors

Summary of positive and negative factors

High price justified

Transforming relationships between parties

Long-term strategies

Patent and regulatory issues

Patent issues

Ethical and regulatory issues

Conclusion

Report Pricing:

Hard Copy EUR 1,669 (US$ 1,560).

Electronic EUR 1,605 (US$ 1,500).

Site Licence EUR 1,605 (US$ 1,500).

ORDERING INFORMATION - FIVE EASY WAYS TO PLACE YOUR ORDER:

ORDER ONLINE: To order this report please click on http://www.researchandmarkets.com/reports/1223 ORDER VIA EMAIL: mailto:orders@researchandmarkets.com ORDER VIA FAX-BACK FORM: Click on http://www.researchandmarkets.com/reports/1223 Fax to +353 14957318 ORDER VIA POST: Click on http://www.researchandmarkets.com/reports/1223 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland ORDER VIA PHONE: Telephone: +353 868797580

REPORT DATA SUMMARY:

Cancer genomics: The impact of genomic advances in oncology Publisher Name: Datamonitor Date Published: 5/31/2002 Category: Biotechnology, Genomics, Genomics, Oncology URL: www.researchandmarkets.com/reports/1223

About Research and Markets Ltd.

Research and Markets Ltd. are Europe's largest resource for industry and market research reports. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends and forecasts.

Major sectors covered include: Banking, Insurance, Pensions, Financial Services, Biotechnology, Genomics, General Business, Advertising, Marketing, Management, Personnel, Company Reports, Competitive Intelligence, Market Intelligence, Strategic Planning, Top 100 Company Lists, Computing, Advanced Technology, Hardware, Software, Construction, Engineering, Consumer, Personal Care, Clothing, Fashion, Household, Furniture, Country Reports (North American, South American, Europe, Africa, China, Asia Pacific, and Middle East), Demographics (Generational and Lifestyle), Energy, Natural Resources, Environmental, Gas, Oil, Power, Mining, Food, Beverage, Agriculture, Food Service, Government, Public Sector, Aerospace, Defence, Education, Healthcare, Medical Devices, Diagnostics, Hospital, Internet, E-Commerce, E-Business, IT Security, New Media, Manufacturing, Industry, Supply Chain and Logistics, Media, Entertainment, Broadcast, Cable, Gaming, Pharmaceuticals, Drug Delivery, Process Industry, Advanced Materials, Chemicals, Paper, Plastics, Retailing, Services Sector, Travel, Telecommunications, Networks, Satellite, Mobile and Wireless, Transport, Shipping, Automotive, and Aviation

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

CONTACT: Holly Swift, Public Relations Manager, Research, Research and Markets Ltd.e-mail: holly.swift@researchandmarkets.com

((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data prepared by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).